NCT03355976View on ClinicalTrials.gov

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 30, 2018

Primary Completion Date

January 31, 2026

Study Completion Date

March 31, 2026

Conditions
Ovarian CancerFallopian Tube CancerPrimary Peritoneal CarcinomaExtra Renal OriginClear Cell Adenocarcinoma
Interventions
DRUG

Nivolumab

240mg flat dose every 2 weeks

DRUG

Ipilimumab

Ipilimumab 1mg/kg every 6 weeks

Trial Locations (4)

60612

University of Illinois Chicago, Chicago

02903

Rhode Island Hospital, Providence

02905

Women & Infants Hospital, Providence

02906

The Miriam Hospital, Providence

Sponsors

Lead Sponsor

Brown University

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Rhode Island Hospital

OTHER

collaborator

The Miriam Hospital

OTHER

collaborator

Women and Infants Hospital of Rhode Island

OTHER

lead

Brown University

OTHER